Evaluation of delgocitinib for the treatment of moderate to severe chronic hand eczema in adults
- Published on 07/27/2026
- Reading time: 1 min.
Nicole Piaskowski , Philipp Globig & Margitta Worm *
Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin, Berlin, Germany
CONTACT Margitta Worm mailto:margitta.worm@charite.de Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany
Abstract
Introduction Chronic hand eczema (CHE) is a frequent inflammatory skin disorder associated with a substantial psychosocial and economic burden. Its prevalence ranges from 4.7% up to 10%. The therapeutic management of CHE remains challenging. Long-term use of topical corticosteroids, which are used as first-line therapy, can be associated with local side effects and a negative impact on the skin barrier. Alitretinoin, a vitamin A derivate licensed as a systemic treatment...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Dermatology
Receive our newsletter to stay up to date with the latest news in Dermatology
